PNC Financial Services Group
ENTA icon

PNC Financial Services Group’s Enanta Pharmaceuticals ENTA Stock Holding History

PNC Financial Services Group’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.02K Sell
556
-230
-29% -$3.08K ﹤0.01% 4115
2025
Q4 		$12.4K Sell
786
-12
-2% -$152 ﹤0.01% 3866
2025
Q3 		$9.55K Buy
798
+127
+19% +$1.01K ﹤0.01% 3963
2025
Q2 		$5.07K Buy
671
+297
+79% +$1.79K ﹤0.01% 4131
2025
Q1 		$2.06K Buy
374
+294
+368% +$1.82K ﹤0.01% 4334
2024
Q4 		$460 Sell
80
-239
-75% -$2.29K ﹤0.01% 4539
2024
Q3 		$3.31K Hold
319
– – ﹤0.01% 4153
2024
Q2 		$4.14K Sell
319
-1,833
-85% -$24.7K ﹤0.01% 4046
2024
Q1 		$37.6K Buy
2,152
+1,938
+906% +$25.6K ﹤0.01% 3122
2023
Q4 		$2.01K Sell
214
-829
-79% -$7.72K ﹤0.01% 4187
2023
Q3 		$11.7K Sell
1,043
-1,728
-62% -$27.8K ﹤0.01% 3688
2023
Q2 		$59.3K Buy
2,771
+1,648
+147% +$48.6K ﹤0.01% 2962
2023
Q1 		$45.4K Buy
1,123
+70
+7% +$3.34K ﹤0.01% 3056
2022
Q4 		$49K Sell
1,053
-4
-0.4% -$182 ﹤0.01% 2992
2022
Q3 		$55K Buy
1,057
+534
+102% +$31.2K ﹤0.01% 2902
2022
Q2 		$25K Sell
523
-617
-54% -$33.5K ﹤0.01% 3374
2022
Q1 		$80K Buy
1,140
+27
+2% +$1.76K ﹤0.01% 2836
2021
Q4 		$84K Buy
1,113
+153
+16% +$12K ﹤0.01% 2807
2021
Q3 		$55K Sell
960
-641
-40% -$31.7K ﹤0.01% 3004
2021
Q2 		$70K Buy
1,601
+814
+103% +$39.9K ﹤0.01% 2860
2021
Q1 		$39K Buy
787
+236
+43% +$11.8K ﹤0.01% 3116
2020
Q4 		$23K Sell
551
-533
-49% -$23.4K ﹤0.01% 3277
2020
Q3 		$49K Buy
1,084
+13
+1% +$630 ﹤0.01% 2750
2020
Q2 		$54K Buy
1,071
+3
+0.3% +$155 ﹤0.01% 2723
2020
Q1 		$56K Buy
1,068
+301
+39% +$16K ﹤0.01% 2557
2019
Q4 		$47K Buy
767
+24
+3% +$1.49K ﹤0.01% 2918
2019
Q3 		$44K Sell
743
-33
-4% -$2.45K ﹤0.01% 2979
2019
Q2 		$65K Buy
776
+34
+5% +$3.06K ﹤0.01% 2791
2019
Q1 		$71K Buy
742
+108
+17% +$9.69K ﹤0.01% 2753
2018
Q4 		$45K Buy
634
+249
+65% +$19.1K ﹤0.01% 2927
2018
Q3 		$33K Buy
385
+15
+4% +$1.5K ﹤0.01% 3229
2018
Q2 		$43K Buy
370
+104
+39% +$10.4K ﹤0.01% 3088
2018
Q1 		$22K Buy
266
+99
+59% +$7.62K ﹤0.01% 3391
2017
Q4 		$10K Sell
167
-3
-2% -$150 ﹤0.01% 3686
2017
Q3 		$8K Sell
170
-68,533
-100% -$2.75M ﹤0.01% 3751
2017
Q2 		$2.47M Sell
68,703
-212
-0.3% -$6.78K ﹤0.01% 928
2017
Q1 		$2.12M Sell
68,915
-15,321
-18% -$477K ﹤0.01% 979
2016
Q4 		$2.82M Buy
84,236
+69,544
+473% +$1.99M ﹤0.01% 858
2016
Q3 		$391K Buy
14,692
+650
+5% +$15.1K ﹤0.01% 1696
2016
Q2 		$310K Buy
14,042
+5,103
+57% +$134K ﹤0.01% 1824
2016
Q1 		$263K Buy
8,939
+1,796
+25% +$50K ﹤0.01% 1924
2015
Q4 		$237K Sell
7,143
-6,038
-46% -$197K ﹤0.01% 1972
2015
Q3 		$477K Sell
13,181
-50
-0.4% -$2.15K ﹤0.01% 1592
2015
Q2 		$594K Buy
13,231
+13,089
+9,218% +$509K ﹤0.01% 1535
2015
Q1 		$4K Sell
142
-5,817
-98% -$226K ﹤0.01% 4077
2014
Q4 		$303K Buy
5,959
+1,659
+39% +$74.3K ﹤0.01% 1831
2014
Q3 		$170K Sell
4,300
-2,423
-36% -$96.6K ﹤0.01% 2089
2014
Q2 		$290K Sell
6,723
-274
-4% -$10.5K ﹤0.01% 1726
2014
Q1 		$280K Buy
+6,997
New +$254K ﹤0.01% 1708

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PNC Financial Services Group's ENTA Position: Q1 2026 in Review

PNC Financial Services Group reduced its Enanta Pharmaceuticals (ENTA) stake by 29% in Q1 2026, selling an estimated $3.08K and leaving 556 shares worth $7.02K. The position accounts for ﹤0.01% of the portfolio, ranked #4115.

PNC Financial Services Group first reported a position in ENTA in Q1 2014 and has held it in 49 quarters since. The position peaked at $2.82M in Q4 2016. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • PNC Financial Services Group held 556 shares of Enanta Pharmaceuticals worth $7.02K as of Q1 2026.
  • PNC Financial Services Group sold 230 Enanta Pharmaceuticals shares in Q1 2026, an estimated $3.08K.
  • Enanta Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4115 holding.
  • PNC Financial Services Group first reported a position in Enanta Pharmaceuticals in Q1 2014 and has held it in 49 quarters since.
  • PNC Financial Services Group's Enanta Pharmaceuticals position peaked at $2.82M in Q4 2016.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.